Contract development and manufacturing organization (CDMO) services offered under the Patheon brand include small molecule API, biologics, viral vectors, cGMP plasmids, formulation, clinical trials solutions, logistics and commercial manufacturing and packaging.

Custom Pharmaceuticals changed its name to Patheon in 1993 and was first publicly traded that year on the Toronto Stock Exchange.

The deal proved unprofitable, and in 2007, the New York equity firm JLL Partners provided Patheon $150 million to restructure.

Two years later, after a failed takeover bid by Lonza Group, JLL Partners bought a controlling interest in the company.

[2] In December 2012, Patheon acquired Banner Pharmacaps, a drug manufacturer specializing in softgels, for $255 million.